AMWAY

Income statement

Revenue CAGR, FY2021–FY2025: −4.83% per annum. Cumulative decline over the four-year period: −18.0%.

Sources: Amway press releases dated 27 Feb 2023 (FY2022, and FY2021 comparative of $8.9B), 5 Mar 2024 (FY2023), 12 Mar 2025 (FY2024), 31 Mar 2026 (FY2025). The 2025 Global Impact Report confirms $7.3B.

Longer-run context: notes and sources

The 2019 figure of $8.4B is an Alticor-group figure including sister companies and is not strictly comparable with the post-2021 Amway direct-selling-only reporting basis. The 2013 peak of ~$11.8B is widely cited and is the reference point for the "years-long slide" narrative in trade coverage. Treat these as indicative, not audited.

Cash flow

Partial capex visibility. Amway has disclosed specific capital programmes rather than an aggregate capex line:

Commentary — trends, inflections, and drivers

The decline is real, sustained, and only partially explicable by currency. Amway has attributed the 2022, 2023, and 2024 declines primarily to US dollar strength, plus two discrete portfolio events (Metagenics divestiture, Russia exit). But the trajectory from a ~$11.8bn peak in 2013 to $7.3bn in 2025 — a decline of roughly 38% over twelve years — cannot be attributed to FX and two one-offs. The underlying driver is structural: erosion of the direct-selling recruitment funnel in developed markets, competition from digital-first commerce and creator-led affiliate models that offer similar income flexibility with far lower friction, and tightened regulatory scrutiny of income claims.

2025 is the inflection worth watching. The −1.4% decline in 2025 is the shallowest of the five-year sequence and follows −9.0%, −4.9%, and −3.9%. Management's framing — "many markets and product launches outperforming forecasts and building positive traction heading into 2026" — is consistent with a stabilisation narrative. Three specific positives support it: beauty grew 8% globally (its first disclosed category growth in years), water treatment grew 25% in the eSpring launch markets, and AmCell delivered "exceptional early sales results" from only three markets. If those three launches scale geographically in 2026–2027, arithmetic alone could return the group to flat-to-positive.

Nutrition is the ballast and the concentration risk simultaneously. At 64% of sales, Nutrilite carries the business. It grew 2% in 2024 while the group fell 3%. The strategic logic of the healthspan/cellular-health pivot is to defend and extend this base. The risk is that 64% concentration in one category, in a VDS market facing intensifying scrutiny of health claims and rising private-label and D2C competition, is a narrow foundation.

Currency exposure is genuine and structural. With top markets ranked China, US, South Korea, Japan, Thailand, Taiwan, Malaysia, India, Vietnam, Central Asia, Amway earns a large majority of revenue in Asian currencies while reporting in USD. Dollar strength in 2022–2024 was a real headwind; any dollar weakening would mechanically flatter 2026–2027 reported results without any operational improvement. Analysts should discount management's currency attributions symmetrically in both directions.

Absence of profitability disclosure is the binding analytical constraint. No conclusion about margin trajectory, cash generation, leverage, or returns is possible. The company's willingness and ability to fund a $127.6m HQ programme, a $100m community commitment, a $33m stadium donation, and $17.7m of annual philanthropy while revenue declines suggests comfortable cash generation and low leverage — but this is inference, not evidence.

Management guidance

None. Amway issues no revenue, margin, or earnings guidance and holds no investor day. Management's only forward statements for 2026 are qualitative: the company enters 2026 "poised to build on its momentum," with "positive traction," and "in a strong position to make the most of the possibilities ahead." The 2025 results release explicitly noted that "many markets and product launches outperform[ed] forecasts."

Consensus expectations

None exist. No sell-side analyst covers Amway. The only external forward view identified is a modelled retail-data projection (ECDB) covering the amway.com e-commerce storefront only, forecasting a marginal decline in 2026 — a metric that captures well under 10% of group revenue and should not be read as a company forecast.

Bull case

1. The decline is decelerating on a clear arithmetic path. Sequential annual changes of −9.0%, −4.9%, −3.9%, −1.4% describe a decelerating curve. A single point of improvement in 2026 returns Amway to growth. The channel itself has stopped contracting: WFDSA reports 2024 global sales essentially flat, with the share of growing markets up from 23% (2022) to 45% (2024).

2. The 2025 launch slate has enormous unexploited geographic runway. AmCell launched in 3 markets and delivered "exceptional early sales results." LongXevity launched in 7 markets and coincided with 8% global beauty growth. The new eSpring launched in 3 named markets and delivered 25% category growth within those markets. Amway operates in 100+ markets. Scaling three validated products across even a fraction of the remaining footprint is a mechanically credible growth path that requires no new invention — only distribution.

3. Category credibility is compounding faster than revenue is declining. Nutrilite went from launching its first cellular-health product in 2025 to being named the world's No. 1 selling cellular health brand by July 2026. That is the fastest category-leadership acquisition in Amway's recent history and evidences that the brand still transfers into new, high-growth adjacencies — while the healthspan narrative, the Lufkin appointment, the Global Wellness Summit sponsorship, and the Major League Pickleball platform give it a coherent, mass-reach consumer expression it has lacked for a decade.

Bear case

1. Twelve years of decline is a trend, not a cycle, and management's explanations have shifted without the trend changing. From ~USD 11.8B (2013) to USD 7.3B (2025) is a 38% contraction. Currency explained 2022–2024; Metagenics and Russia explained 2022–2023. None of these explain 2013–2021. Crucially, Amway disclosed a constant-currency organic growth figure in 2023 (+1.0% for 2022) and has not repeated that disclosure in any of the three subsequent results releases — a conspicuous omission for a company that continues to attribute reported declines to currency.

2. India demonstrates that a top-ten market can deteriorate on multiple axes simultaneously, and nothing structurally prevents recurrence. India's revenue from operations fell 10.56% to INR 1,148.16 crore in FY2025 with net loss widening to INR 74.25 crore, while the company faces a PMLA chargesheet alleging over INR 4,000 crore in proceeds of crime, has INR 757–758 crore of assets attached, and confronts organised political advocacy for restricting the MLM model outright. India is Amway's eighth-largest market and its stated top-three aspiration. If a market can go from growth aspiration to shrinking-and-criminally-investigated, the same regulatory and political dynamics apply in principle across the seven Asian markets that carry the business — including China, which banned the model outright once before.

3. The recruitment engine's own economics are publicly weak and structurally under attack. Amway's disclosed 2024 income figure — USD 1,199 average annual earnings before expenses for members who recorded at least one sale — is the proposition on which one million ABOs must be continuously replenished. That proposition now competes against creator-economy and affiliate models offering comparable flexibility with no inventory, no downline, and no reputational cost, in a regulatory environment (post-2021 FTC guidance) that holds the company accountable for what its distributors claim. Meanwhile Amway has made no acquisition in five years while Herbalife made three in one, and Amway has been losing share within a shrinking channel (−17% versus the channel's −12% over 2021–2024).

Catalysts and monitorables, next 12 months

Analyst verdict

Amway is a structurally sound but strategically cornered business. The asset base is genuinely differentiated: ~6,000 acres of certified-organic farmland, five manufacturing plants, 800+ technical staff, 750+ patents, and two externally verified No. 1 global brand positions in vitamins and in cellular health. Very few consumer companies of any size own their supply chain from seed to shelf. That is a real, durable moat around the product.

The problem is not the product. It is the channel. Amway has declined for five consecutive years and for roughly twelve of the last thirteen, from ~USD 11.8B to USD 7.3B. Over 2021–2024 it lost share within a channel that was itself contracting. Management attributes this to currency; the company's quiet abandonment of the constant-currency organic disclosure it made in 2023 suggests the underlying picture is less flattering than the reported one. Meanwhile the recruitment proposition — an average USD 1,199 in annual pre-expense earnings, on Amway's own numbers — must now compete with creator-economy commerce that offers the same flexibility without inventory, downline, or stigma.

There is a credible bull case, and it is narrower than it looks: the 2025 launches worked, and they worked in three, seven, and three markets out of a hundred-plus. Scaling proven products across an existing footprint is the lowest-risk growth available to any consumer company. If Amway executes only that, the arithmetic returns it to growth.

Two things would change the verdict. An adverse outcome in the India PMLA proceedings would be damaging well beyond India. Conversely, a flat or positive FY2026 print accompanied by a reinstated organic growth disclosure would be the first genuine evidence in over a decade that the decline has ended.

Verdict: stabilising, not yet recovering. Watch the March 2027 release and the market-count of AmCell and LongXevity — not the narrative.

---

SOURCE NOTE AND DATA QUALITY ASSESSMENT

Primary sources used: Amway Corp press releases (27 Feb 2023, 5 Mar 2024, 12 Mar 2025, 30 Sep 2024, 4 Aug 2025, 25 Jun 2026, 31 Mar 2026, 23 Jul 2026); Amway Global Impact Report 2024 (and At-a-Glance Fact Sheet) and Global Impact Report 2025; Amway leadership and newsroom pages (accessed 9 September 2026); Amway India Enterprises Pvt Ltd statutory filings as reported in Indian business press.

Industry sources: World Federation of Direct Selling Associations STATS Report (published Nov/Dec 2025, covering 2024); Direct Selling News Global 100, 2026 edition (covering 2025 revenue); GlobalData brand-ranking claims as cited by Amway at gdretail.net/amway-claims; Euromonitor International (cumulative bonus figure, as cited by Amway).

Secondary sources: Business Standard; WOOD TV8; SupplySide Supplement Journal; Nutraceuticals World; Women's Wear Daily; Deccan Herald; Wikipedia (corporate structure, used only for uncontested historical facts and cross-checked where possible).

ECDB retailer data was examined but is a modelled e-commerce GMV estimate for the amway.com storefront only, irreconcilable with the company-reported group figure, and is flagged rather than used. they could not be corroborated against court dockets, regulator publications, or reputable press.